It is currently unknown how increased life expectancy or restoration of CFTR function for those on CFTR modulator therapies will affect the prevalence of CFLD, though some studies have shown that incidence of CFLD continues throughout adulthood, highlighting the need for ongoing CFLD screening in adults with CF [2,6]. The gene discussed is CFTR; the disease is cystic fibrosis-related liver disease.